• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

    5/14/25 10:34:49 AM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    PROTHENA CORP PUBLIC LTD CO

    (Name of Issuer)


    Ordinary Shares, $0.01 par value

    (Title of Class of Securities)


    G72800108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G72800108


    1Names of Reporting Persons

    SCULLY WILLIAM P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    793,943.00
    6Shared Voting Power

    4,813,805.00
    7Sole Dispositive Power

    793,943.00
    8Shared Dispositive Power

    4,813,805.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,607,748.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.4 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4 as to disclaimer of beneficial ownership.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PROTHENA CORP PUBLIC LTD CO
    (b)Address of issuer's principal executive offices:

    77 SIR JOHN ROGERSON'S QUAY, BLOCK C, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, IRELAND, D02 VK60.
    Item 2. 
    (a)Name of person filing:

    William P. Scully
    (b)Address or principal business office or, if none, residence:

    771 Manatee Cove, Vero Beach, Florida 32963
    (c)Citizenship:

    Florida
    (d)Title of class of securities:

    Ordinary Shares, $0.01 par value
    (e)CUSIP No.:

    G72800108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The Reporting Person may be deemed to be the beneficial owner of 5,607,748 Ordinary Shares. This amount consists of (i) 34,993 Ordinary Shares owned directly by the Reporting Person over which he has sole voting and dispositive power, (ii) 75,950 Ordinary Shares owned by Manatee Equity Fund LLC, of which the Reporting Person is the sole manager with sole voting and dispositive power, (iii) 683,000 Ordinary Shares owned by the Reporting Persons IRA, over which he has sole voting and dispositive power, (iv) 42,000 Ordinary Shares owned by the Reporting Persons spouses IRA, over which he may be deemed to have shared voting and dispositive power, (v) 5,000 Ordinary Shares owned by the Reporting Persons spouse, over which he may be deemed to have shared voting and dispositive power (vi) 18,000 Ordinary Shares owned by an IRA subject to an investment management agreement over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his right to terminate such agreement, (vii) 158,000 Ordinary Shares owned in the aggregate by various trusts, of which the Reporting Person may be deemed to have shared voting and dispositive power by virtue of being a co-trustee, (viii) 4,098,346 Ordinary Shares owned in the aggregate by various grantor retained annuity trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts, and (ix) 492,459 Ordinary Shares owned in the aggregate by various other trusts, which have an independent trustee, but over which the Reporting Person may be deemed to have shared voting and dispositive power by reason of his retained right to substitute assets in such trusts.
    (b)Percent of class:

    According to the Issuers most recent Annual Report on Form 10-K for the year ended December 31, 2024, the number of shares outstanding as of February 20, 2025 was 53,826,982. The Ordinary Shares which the Reporting Person may be deemed to beneficially own constitute approximately 10.42 percent of such total number of shares.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    793,943

     (ii) Shared power to vote or to direct the vote:

    4,813,805

     (iii) Sole power to dispose or to direct the disposition of:

    793,943

     (iv) Shared power to dispose or to direct the disposition of:

    4,813,805

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SCULLY WILLIAM P
     
    Signature:Diana L. Hayes
    Name/Title:By POA from William P. Scully
    Date:05/14/2025

    Comments accompanying signature:  Pursuant to a Limited Power of Attorney dated as of February 13, 2024, a copy of which is on file with the Commission.
    Get the next $PRTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    1/27/2023$94.00Overweight
    Piper Sandler
    11/4/2022$52.00 → $55.00Outperform → Sector Perform
    RBC Capital Mkts
    9/28/2022Neutral → Buy
    BofA Securities
    11/19/2021$77.00Market Outperform
    JMP Securities
    More analyst ratings

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prothena Reports First Quarter 2025 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statistical significance level of 0.10 Multiple clinical readouts for PRX012, a potential single-injection once-monthly subcutaneous treatment for millions of patients with presymptomatic or early symptomatic Alzheimer's disease, expected starting around mid-

      5/8/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

      Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

      2/20/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

      11/12/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports First Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

      5/8/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Appoints David Ford to Newly Created Chief People Officer Position

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

      3/4/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/14/24 1:22:34 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 7:00:50 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 6:06:27 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/2/25 10:29:05 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ecor1 Capital, Llc sold $50,839,807 worth of Ordinary Shares (6,279,684 units at $8.10) (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/6/25 7:06:05 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/2/25 10:29:05 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Scully William P claimed ownership of 1,037,207 units of Ordinary Shares (SEC Form 3)

      3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/1/25 9:19:59 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Prothena with a new price target

      Chardan Capital Markets initiated coverage of Prothena with a rating of Buy and set a new price target of $40.00

      12/20/24 7:48:38 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena downgraded by BofA Securities with a new price target

      BofA Securities downgraded Prothena from Buy to Neutral and set a new price target of $38.00 from $68.00 previously

      1/30/24 7:38:21 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Prothena with a new price target

      Deutsche Bank initiated coverage of Prothena with a rating of Buy and set a new price target of $62.00

      12/12/23 8:06:31 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

      SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      5/14/25 10:34:49 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Prothena Corporation plc

      10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/8/25 4:15:12 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/8/25 4:10:38 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Financials

    Live finance-specific insights

    See more
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

      Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

      2/20/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

      2/13/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care